
Teens Oversleeping Post-Concussion May Have Worse Recovery
Kids and teens sleeping longer, even as little as an hour more, during the first week after a concussion were more likely to have worse cognitive and somatic symptoms. Sleeping longer was also linked to persistent symptoms and slower recovery.
METHODOLOGY:
Researchers used data from a randomized clinical trial that took place across three emergency pediatric departments in Ontario, Canada, over a 2-year period beginning in March 2017.
The study included 291 kids and teens between the ages of 10 and 18 years (median age, 13.2 years; 44% female) who received treatment for a concussion within 48 hours of injury.
Each patient wore an accelerometer on their waist 24 hours a day for 2 weeks and completed sleep logs to monitor sleep patterns.
Symptoms were tracked using the Health and Behavior Inventory (HBI), a questionnaire that measures cognitive and somatic symptoms at 1 , 2 , and 4 weeks following their concussion.
Symptom change was measured using conservative (z score ≥ 1.65) and liberal (z score ≥ 1.28) cutoffs; estimates were measured in HBI units.
TAKEAWAY:
Kids and teens who slept 10.5 vs 9.5 hours per night during the first week after a concussion had higher symptom scores at 1 week (estimate, 1.3; 95% CI, 0.25-2.28).
Longer sleep duration was linked to higher odds of persisting symptoms at 4 weeks (conservative: odds ratio [OR], 1.73; 95% CI, 0.91-3.26; liberal: OR, 1.93; 95% CI, 1.07-3.47).
Teens who slept 10.9 vs 9.9 hours were more likely to have increased symptoms at 4 weeks (estimate, 2.2; 95% CI, 0.85-3.47).
IN PRACTICE:
'Long sleep duration may be associated with increased odds of being reliably symptomatic at 4 weeks, therefore a greater risk of PSAC [persisting symptoms after a concussion],' the study authors wrote. 'Clinicians should monitor youths' sleep after concussion.'
SOURCE:
This study was led by Lauren Butterfield, MSc, of the Children's Hospital of Eastern Ontario Research Institute in Ottawa, Canada. It was published online on June 18 in JAMA Network Open.
LIMITATIONS:
The HBI used for symptom assessment is not validated for youths older than 16.99 years, and 16 participants were older than 17 years. Recruitment from three Canadian pediatric emergency departments may have introduced sampling bias.
DISCLOSURES:
Various study authors reported receiving stipend support, research grants, and travel awards from the Children's Hospital of Eastern Ontario Research Institute, the Canadian Institutes of Health Research, and the Canadian Concussion Network, among others.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ('Revive' or the 'Company') (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for infectious diseases and medical countermeasures, hereby clarifies its update regarding the research study assessing Bucillamine as a potential treatment for nerve agent exposure. This study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre ('DRDC'), an agency of the Canadian Department of National Defence, which is investigating pharmacological compounds, including Bucillamine, capable of mitigating nerve agent-induced brain injury. The research study with Bucillamine is slated for continuation through September 2025, and its findings will be disseminated exclusively with the express authorization of the DRDC. The Company affirms that future research endeavours with DRDC have not been broached and would only be deliberated subsequent to the conclusion of the current research study and contingent upon the satisfactory nature of its results, warranting further investigation. About Revive Therapeutics Ltd. Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. For more information, visit For more information, please contact: Michael FrankChief Executive OfficerRevive Therapeutics 1 888 901 0036Email: mfrank@ Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words 'may', 'could', 'intend', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive's current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company's cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading 'Risk Factors' in the Company's management's discussion and analysis for the three and nine months ended March 31, 2025 ("MD&A"), dated May 29, 2025, which is available on the Company's profile at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Connexall Now Available in Epic Toolbox as Alert Manager Solution
Milestone Underscores Connexall's Seamless Integration with Epic for Clinical Alerting and Interoperability TORONTO, July 08, 2025--(BUSINESS WIRE)--Connexall, a global leader in clinical communication, alarm management, and workflow optimization, today announced its designation in the "Alert Manager Integration" category in Epic Toolbox on Showroom. This achievement highlights Connexall's expertise in driving seamless integration with disparate systems to provide intelligently routed clinical and operational alerts directly into Epic – including Rover, Haiku, and Canto. Connexall collaborated with Epic to provide input into the design of the Alert Manager Integration blueprint, which defines Epic's recommended practices for products in this category. Within Showroom, Toolbox is a designation for products that use established integration technology in select categories to meet Epic defined recommended connection practices for that area. The eligible categories focus on the most impactful and innovative areas for Epic customers. Connexall's integration platform provides deep interoperability and proven outcomes for health systems looking to streamline alert management and reduce alarm fatigue. "This recognition by Epic demonstrates Connexall's commitment to improving clinical workflows, patient safety, and staff and clinician satisfaction for over 25 years," said Connexall CEO Sandy Saggar. "We are honored to support the standard in the Alert Manager Integration category in the Epic Toolbox." With its extensive integration library, Connexall offers bi-directional integration with Epic and consolidates alerts from various systems—such as nurse call, patient monitoring, IV pumps, RTLS, and smart beds—ensuring the right information reaches the right care team member, on the right device, at the right time. This milestone reaffirms Connexall's role in the healthcare ecosystem—alleviating burden, increasing efficiency, and improving patient care. About Connexall Connexall is a connected care and interoperability platform, seamlessly integrating disparate healthcare technologies. As a vendor-neutral solution, Connexall intelligently manages alarms and optimizes workflows to improve staff experience and patient safety. To learn more, visit Epic, Rover, Canto, and Haiku are registered trademarks of Epic Systems Corporation. View source version on Contacts Media Contact: Amira Melnichenkoamelnichenko@ 321-247-3940 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Ancient Menominee grew tropical corn farther north than expected, surprising researchers
In a stunning discovery — both in agricultural sophistication and geographic location — researchers have found ancestors of the Menominee Nation of Wisconsin were growing tropical corn in Michigan's Upper Peninsula about 1,000 years ago. Last month Dartmouth researchers discovered the most complete ancient agricultural site so far in the eastern half of the U.S., along the Menominee River just across the Wisconsin border. Researchers said the Sixty Islands archaeological site features a raised ridge field system, with a more extensive maize, or corn, system than anyone imagined. It is a tropical plant, and many Western researchers previously believed it was mostly grown in tropical to subtropical regions. They were astounded that Menominee could grow so much in a cold climate with a relatively short growing season. 'The scale of this agricultural system by ancestral Menominee communities is 10 times larger than what was previously estimated,' said lead author Madeleine McLeester, an assistant professor of anthropology at Dartmouth, in a published article. 'That forces us to reconsider a number of preconceived ideas we have about agriculture not only in the region, but globally.' Beans and squash also were grown at the site, completing the 'Three Sisters' farming system created by Indigenous peoples. The crops work together naturally to protect each other from pests and disease. 'When you look at the scale of farming, this would require the kind of labor organization that is typically associated with a much larger, state-level hierarchical society,' said McLeester in the Dartmouth article. 'Yet, everything we know about this area suggests smaller egalitarian societies lived in this region. But, in fact, this may have been a rather large settlement.' The site is part of what's known to Menominee as Anaem Omot, translated to 'Dog's Belly,' and is where Menominee believe they were created near the mouth of the Menominee River at least 10,000 years ago. Along with raised ancient agricultural fields, the site also contains burial mounds, hammered metal artifacts, unmarked graves, ancient medicine lodges and dance rings associated with the Menominee Dream Dance. It remains a place of spiritual pilgrimage for Menominee living in Wisconsin. For years, the Menominee Nation has fought against mining at the site. Canada-based Aquila Resources had hoped to start its Back 40 Mine, which would extract gold, silver, zinc and copper. Aquila Resources was acquired in 2021 by Gold Resource Corporation. The Menominee has argued it would harm the environment, in particular affecting the region's water, which is historically significant to the tribe. With the help of Menominee Tribal Historic Preservation Officer David Grignon and the late archaeologist David Overstreet, the tribe was able to convince Western authorities to place the site on the National Register of Historic Places in 2023. The designation creates an extra layer of protection from harmful development. 'It was a long time in coming, but now our sacred sites, mounds and historic sites on the Menominee River at Sixty Islands are recognized,' Grignon said. Stefanie Tsosie, an attorney with Earthjustice, which has helped the tribe, said the historic designation is the same kind found in many cities usually represented by plaques on historic buildings. 'It doesn't outright prevent development,' she said. 'It's just an extra layer of regulation or extra layer of consideration that needs to happen.' This article originally appeared on Milwaukee Journal Sentinel: Menominee grew tropical corn farther in U.P., stunning researchers